ArticleDiagnostic pathology2017
Gene expression profiling in uveal melanoma: technical reliability and correlation of molecular class with pathologic characteristics.
Article in Diagnostic pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Review
- Early genetic evolution of driver mutations in uveal melanoma.Nature communications · 2025Article
- Clinical Implications of Ultrasound-Based Morphology in Choroidal Melanoma.Ophthalmology. Retina · 2025Article
- An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma.Biomolecules · 2025Article
- PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma.Investigative ophthalmology & visual science · 2023Article
- Investigating Vitreous Cytokines in Choroidal Melanoma.Cancers · 2023Article
- Clinical Applications of Machine Learning in the Management of Intraocular Cancers: A Narrative Review.Investigative ophthalmology & visual science · 2023Review
- Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma.Ophthalmology · 2023Article
- Diagnostic Aqueous Humor Proteome Predicts Metastatic Potential in Uveal Melanoma.International journal of molecular sciences · 2023Article
- Genetics and RNA Regulation of Uveal Melanoma.Cancers · 2023Review
- Uveal melanoma patient attitudes towards prognostic testing using gene expression profiling.Melanoma management · 2022Article
- Analytical Validation and Performance of a 7-Gene Next-Generation Sequencing Panel in Uveal Melanoma.Ocular oncology and pathology · 2021Article
- Gene Expression Profiling in Uveal Melanoma: Five-Year Prospective Outcomes and Meta-Analysis.Ocular oncology and pathology · 2020Article
- Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling.Melanoma management · 2020Article
- BAP1 Immunoreactivity Correlates with Gene Expression Class in Uveal Melanoma.Ocular oncology and pathology · 2020Article
- ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report.American journal of ophthalmology case reports · 2020Article
- CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA.Retina (Philadelphia, Pa.) · 2020Article
- Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker.American journal of ophthalmology · 2019Article
- Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma.American journal of ophthalmology · 2018Article
- Is Collaborative Ocular Melanoma Study (COMS) still relevant?Indian journal of ophthalmology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA 15-gene expression profile test has been clinically validated and is widely utilized in newly diagnosed uveal melanoma (UM) patients to assess metastatic potential of the tumor. As most patients are treated with eye-sparing radiotherapy, there is limited tumor tissue available for testing, and technical reliability and success of prognostic testing are critical. This study assessed the analytical performance of the 15-gene expression test for UM and the correlation of molecular class with pathologic characteristics.
methodsInter-assay, intra-assay, inter-instrument/operator, and inter-site experiments were conducted, and concordance of the 15-gene expression profile test results and associated discriminant scores for matched tumor samples were evaluated. Technical success was determined from de-identified clinical reports from January 2010 - May 2016. Pathologic characteristics of enucleated tumors were correlated with molecular class results.
resultsInter-assay concordance on 16 samples run on 3 consecutive days was 100%, and matched discriminant scores were strongly correlated (R
conclusionsThese results show that the 15-gene expression profile test for UM has robust, reproducible performance characteristics. The technical success rate during clinical testing remains as high as first reported during validation. As molecular testing becomes more prevalent for supporting precision medicine efforts, high technical success and reliability are key characteristics when testing such limited and precious samples. The performance of the 15-gene expression profile test in this study should provide confidence to physicians who use the test's molecular classification to inform patient management decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.